Condition: Candidiasis · Fungal Infection · Acute Myeloid Leukemia · Sponsor: Bochud Pierre-Yves
This is a prospective genetically-stratified randomized double-blind event-driven multicentre clinical trial to assess the efficacy of posaconazole-based antifungal prophylaxis allocation strategies for patients with acute myeloid leukemia who receive induction chemotherapy. Allocation strategy based on an invasive mold infection genetic risk will be double-blinded.
This description comes directly from the study's public registry record.
Pierre-Yves Bochud, MD · 0041 213144379 · Pierre-Yves.Bochud@chuv.ch
Always discuss trial participation with your own doctor first.
| Ghent University Hospital | Ghent, Belgium, Belgium | Terminated |
| AZ Sint-Jan Hospital | Bruges, Belgium | Recruiting |
| University Hospital Leuven (UZ Leuven) | Leuven, Belgium | Recruiting |
| Henri Mondor Hospital | Créteil, Île-de-France Region, France | Recruiting |
| Cantonal Hospital Aarau | Aarau, Aarau, Switzerland | Recruiting |
| University Hospital Basel | Basel, Basel, Switzerland | Recruiting |
| Cantonal Hospital HFR | Fribourg, Canton of Fribourg, Switzerland | Recruiting |
| University Hospital of Geneva (HUG) | Geneva, Canton of Geneva, Switzerland | Recruiting |
| University Hospital of Lausanne / Centre Hospitalier Universitaire Vaudois (CHUV) | Lausanne, Canton of Vaud, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03828773